Table 1.
Clinical and laboratory characteristics of patients with provisional low-risk ALL.
| Characteristic | Final risk-Low risk | Final risk- Intermediate/high risk | All patients | ||||
|---|---|---|---|---|---|---|---|
| Single-dose group | Double-dose group | P value | Single-dose group | Double-dose group | P value | ||
| Age, y | |||||||
| Median | 4.2 (1.1-12.0) | 4.7 (1.1-15.8) | 0.000 | 4.1 (1.5-9.3) | 4.7 (1.1-11.7) | 0.025 | 4.1(1.1-15.8) |
| Sex | |||||||
| Male | 295 (57.5%) | 872 (58.9%) | 0.575 | 46 (52.9%) | 190 (60.1%) | 0.224 | 1403(58.6%) |
| Female | 218 (42.5%) | 608 (41.1%) | 41 (47.1%) | 126 (39.9%) | 993(41.4%) | ||
| WBC count, ×109/L | |||||||
| Median | 16.4 (0.6-234.7) | 11.0 (0.3-237.0) | 0.000 | 11.2 (1.2-57.6) | 13.8 (1.0-125.2) | 0.172 | 12.5(0.3-237.0) |
| Meet the criteria* | |||||||
| Yes | 23 (4.5%) | 1217 (82.2%) | 0.000 | 2 (2.3%) | 216 (68.4%) | 0.000 | 1458 (60.9%) |
| No | 490 (95.5%) | 263 (17.8%) | 85 (97.7%) | 100 (31.6%) | 938 (39.1%) | ||
| Molecular or cytogenetic abnormalities | |||||||
| ETV6-RUNX1 | 189 (36.8%) | 467 (31.6%) | 0.000 | 16 (18.4%) | 59 (18.7%) | 0.478 | 731 (30.5%) |
| Hyperdiploidy | 154 (30.0%) | 359 (24.2%) | 31 (35.6%) | 92 (29.1%) | 636 (26.5%) | ||
| B lineage, other | 170 (33.2%) | 654 (44.2%) | 40 (46.0%) | 165 (52.2%) | 1029 (43.0%) | ||
| MRD at d 19, % | |||||||
| < 0.1 | 391 (76.2%) | 1207 (81.6%) | 0.009 | 0 | 0 | 0.464 | 1598 (66.7%) |
| 0.1~0.99 | 122 (23.8%) | 273 (18.4%) | 19 (21.8%) | 58 (18.4%) | 472 (19.7%) | ||
| ≥1 | 0 | 0 | 68 (78.2%) | 258 (81.6%) | 326 (13.6%) | ||
| MRD at d 46, % | |||||||
| <0.01 or not performed | 501 (97.7%) | 1444 (97.6%) | 0.905 | 38 (43.7%) | 151 (47.8%) | 0.497 | 2134 (89.1%) |
| ≥ 0.01 | 12 (2.3%) | 36 (2.4%) | 49 (56.3%) | 165 (52.2%) | 262 (10.9%) | ||
*The criteria for the second dose of daunorubicin (WBC > 1.0×109/L and ANC > 0.3×109/L).